Seven Innovent Biologics Innovative Drugs Included in 2026 National Medical Insurance Directory
nashnova research
Innovent Biologics (01801) placed seven innovative drugs on China's 2026 national medical insurance catalogue — four of them for the first time — lifting its reimbursed total to 17 products. The paywall is down; the real test is whether prescriptions follow.
Which drugs made it in?
Four first-time entries: weight-loss/metabolic drug Xinermei® (mazdutide), a GCG/GLP-1 dual-receptor agonist — an injection that activates two gut-hormone receptors to control blood sugar and body weight; autoimmune drug Xinmeiyue® (picankibart), an IL-23p19 inhibitor; immuno-oncology drug Dabaixing® (ipilimumab), a CTLA-4 inhibitor; and blood-cancer drug Weifutai® (quizartinib), a type-II FLT3 inhibitor.
Two existing drugs added new indications: PD-1 flagship Tyvyt® (sintilimab) and BTK inhibitor Jiepali® (pirtobrutinib). Cholesterol drug Xinbile® (tafolecimab) renewed its listing.
This means → Innovent secured four "new entry tickets" plus three "expansion tickets" in a single round — seven drugs landed at once, spanning oncology, cardio-metabolic, and autoimmune diseases.
What do 17 listed drugs mean?
Including these seven, Innovent now has 17 innovative drugs on the national reimbursement list. The company says it has cumulatively served over 20 million patients.
In plain terms = the reimbursement catalogue is a drugmaker's "sales pass" — once a drug is listed, hospitals are willing to prescribe at scale and patients pay less out of pocket. Seventeen products on the list signals that Innovent's commercial pipeline has real breadth.
This reflects an accelerating shift from R&D-driven to commercialization-driven growth.
What does each new drug target?
Xinermei® (mazdutide): a GCG/GLP-1 dual-agonist injection competing in the same lane as semaglutide, aimed at weight loss and type-2 diabetes.
Xinmeiyue® (picankibart): an IL-23 inhibitor for psoriasis and other autoimmune conditions. Dabaixing® (ipilimumab): a CTLA-4 inhibitor for combination immunotherapy in kidney cancer, colorectal cancer, and other solid tumors.
Weifutai® (quizartinib): targets FLT3-mutant acute myeloid leukemia — a blood cancer driven by a specific gene mutation.
This means → the four drugs sit in four distinct therapeutic lanes. Innovent is not betting on a single blockbuster — it is spreading across multiple fields at once.
Does getting listed guarantee strong sales?
Not necessarily. Reimbursement solves the "can it be covered?" question. But between listing and actual volume growth lie hospital formulary adoption, physician prescribing habits, and patient awareness.
Innovent itself acknowledges that converting payer access into clinical uptake is the key checkpoint for proving commercial value.
In plain terms = winning a spot on the catalogue is like getting shelf space in a supermarket — the product is on the shelf, but how much consumers buy still depends on marketing and the competitive landscape. Catalogue inclusion is the starting line, not the finish.
市场有风险,内容仅供研究参考,不构成投资建议。
